Cas:919363-04-5 6-isoquinolin-5-yl-N-(2-methoxyethyl)naphthalene-1-carboxamide manufacturer & supplier

Chemical Name:6-isoquinolin-5-yl-N-(2-methoxyethyl)naphthalene-1-carboxamide

CAS.NO:919363-04-5

Synonyms:6-isoquinolin-5-yl-N-(2-methoxyethyl)naphthalene-1-carboxamide

Molecular Formula:C₂₃H₂₀N₂O₂

Molecular Weight:356.41700

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:54.71000

Exact Mass:356.15200

LogP:5.00600

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 6-isoquinolin-5-yl-N-(2-methoxyethyl)naphthalene-1-carboxamide chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,6-isoquinolin-5-yl-N-(2-methoxyethyl)naphthalene-1-carboxamide physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,6-isoquinolin-5-yl-N-(2-methoxyethyl)naphthalene-1-carboxamide Use and application,6-isoquinolin-5-yl-N-(2-methoxyethyl)naphthalene-1-carboxamide technical grade,usp/ep/jp grade.

Related News: A combination of Imbruvica and AbbVie and Roche’s Venclexta slashed the risk of cancer progression or death by 78.4% compared with a cocktail of Roche’s Gazyva and the chemotherapy chlorambucil in previously untreated CLL. The data, from the phase 3 GLOW trial, were shared at the European Hematology Association (EHA) annual meeting. 6-isoquinolin-5-yl-N-(2-methoxyethyl)naphthalene-1-carboxamide manufacturer A combination of Imbruvica and AbbVie and Roche’s Venclexta slashed the risk of cancer progression or death by 78.4% compared with a cocktail of Roche’s Gazyva and the chemotherapy chlorambucil in previously untreated CLL. The data, from the phase 3 GLOW trial, were shared at the European Hematology Association (EHA) annual meeting. 6-isoquinolin-5-yl-N-(2-methoxyethyl)naphthalene-1-carboxamide supplier The iLet is designed to function as three medical devices in one. It can be configured as an insulin-only bionic pancreas, a glucagon-only bionic pancreas, or a bihormonal bionic pancreas using insulin and glucagon. 6-isoquinolin-5-yl-N-(2-methoxyethyl)naphthalene-1-carboxamide vendor A combination of Imbruvica and AbbVie and Roche’s Venclexta slashed the risk of cancer progression or death by 78.4% compared with a cocktail of Roche’s Gazyva and the chemotherapy chlorambucil in previously untreated CLL. The data, from the phase 3 GLOW trial, were shared at the European Hematology Association (EHA) annual meeting. 6-isoquinolin-5-yl-N-(2-methoxyethyl)naphthalene-1-carboxamide factory If the results from that trial are positive, the company might apply to the U.S. Food and Drug Administration for the same accelerated approval pathway recently used to bring the controversial Alzheimer’s drug aducanumab to market, Novak said.